# EDGAR Filing Document

**Accession Number:** 0001851484
**File Stem:** 0001213900-25-064047
**Filing Date:** 2025-7
**Character Count:** 2977
**Document Hash:** 59e0c78e32260af47530441bcd730429
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-064047.hdr.sgml**: 20250813

**ACCESSION NUMBER**: 0001213900-25-064047

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250715

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CITIUS ONCOLOGY, INC.
- **CENTRAL INDEX KEY:** 0001851484
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 11 COMMERCE DRIVE
- **STREET 2:** 1ST FLOOR
- **CITY:** CRANFORD
- **STATE:** NJ
- **ZIP:** 07016
- **BUSINESS PHONE:** (908) 967-6677

**MAIL ADDRESS:**
- **STREET 1:** 420 LEXINGTON AVE,
- **STREET 2:** SUITE 2446
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TenX Keane Acquisition
- **DATE OF NAME CHANGE:** 20210315

**CITIUS ONCOLOGY, INC.**

**11 Commerce Drive, First Floor**

**Cranford, NJ 07016**

July 15, 2025

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jessica Dickerson

---

| | |
|:---|:---|
| **Re:** | **Acceleration Request**<br> **Citius Oncology, Inc.**<br> **Registration Statement on Form S-1**<br> **Filed July 14, 2025, as amended on July 14, 2025**<br> **File No. 333-288656** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), Citius Oncology, Inc. (the "Registrant") hereby requests that the U.S. Securities and Exchange Commission (the "Commission") take appropriate action to accelerate the effective date of the above-referenced registration statement (the "Registration Statement") so as to become effective on Tuesday, July 15, 2025 at 5:00 p.m. Eastern Time, or as soon thereafter as practicable.

The Registrant hereby authorizes Alexander M. Donaldson, Jonathan Greene, Andrew Gibbons, Nicholas Massey and/or Christopher P. Agoranos of Wyrick Robbins Yates & Ponton LLP to orally modify or withdraw this request for acceleration.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Alexander M. Donaldson or Nicholas Massey at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Mr. Donaldson via email at adonaldson@wyrick.com and Mr. Massey via email at nmassey@wyrick.com.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| CITIUS ONCOLOGY, INC. | CITIUS ONCOLOGY, INC. |
| By: | /s/ Leonard Mazur |
|  | Leonard Mazur |
|  | Chairman and Chief Executive Officer |

---

cc: Alexander M. Donaldson, Wyrick Robbins Yates & Ponton LLP